Study to Investigate Luveltamab Tazevibulin in Adults with Advanced or Metastatic Non-small Cell Lung Cancer

Inclusion Criteria:

• Histologically or cytologically confirmed non-squamous/adenocarcinoma oradenosquamous NSCLC that is either unresectable Stage IIIb/c disease not amenablefor definitive chemoradiation, or Stage IV.

• Age ≥ 18 years

• ECOG performance status 0 to 1.

• Received at least 2 but no more than 4 prior lines of systemic therapy for advancedNSCLC

• Disease progression during or following the most recent systemic anti-cancertherapy.

• Positive FOLR1 expression per central testing

• At least 1 measurable target lesion per RECIST 1.1

• Adequate organ function

Exclusion Criteria:

• Prior treatment with a FOLR1- targeting ADCs or with ADCs that contain a tubulininhibitor

• Untreated central nervous system metastases

• Ongoing immunosuppressive therapy, except for treated brain metastases, percriterion above.

• History of severe allergic or anaphylactic reactions to monoclonal antibody therapyor to antibody-related fusion protein treatment

• Pre-existing clinically significant ocular disorders, severe chronic obstructivepulmonary disease or asthma, clinically significant cardiac or cerebrovasculardisease, or other significant concurrent, uncontrolled medical condition

• Previous solid organ transplantation

• Concurrent participation in another therapeutic treatment trial